In 2019, the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD), and European Society of Cardiology (ESC) published updated recommendations for the management of patients with T2DM and a high cardiovascular risk, highlighting the cardiorenal benefits of SGLT2i and glucagon-like peptide-1 receptor agonists (GLP-1 RA) (171–174). The gene discussed is GCG; the disease is diabetes mellitus.